Bicara Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
Provided By GlobeNewswire
Last update: Nov 12, 2024
On track to initiate FORTIFI-HN01, a pivotal Phase 2/3 trial of ficerafusp alfa in 1L R/M HNSCC
Completed upsized initial public offering, raising approximately $362 million in gross proceeds, with full exercise of the underwriters’ option to purchase additional shares
Read more at globenewswire.com
